Blair William & Co. IL Sells 3,863 Shares of Axon Enterprise, Inc (NASDAQ:AXON)

Key Points

• Blair William & Co. IL reduced its stake in Axon Enterprise by 4.2%, owning approximately 0.11% of the company, worth $46.1 million as of the latest SEC filing.
• Axon Enterprise reported $1.41 earnings per share (EPS), surpassing analysts' expectations of $1.34, alongside a revenue increase of 31.3% year-over-year.
• Institutional investors hold 79.08% of Axon Enterprise's stock, with recent significant increases in stakes from various hedge funds in the fourth quarter.

Blair William & Co. IL decreased its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 4.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 87,584 shares of the biotechnology company's stock after selling 3,863 shares during the quarter. Blair William & Co. IL owned 0.11% of Axon Enterprise worth $46,065,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in AXON. Kentucky Retirement Systems Insurance Trust Fund bought a new stake in shares of Axon Enterprise in the first quarter worth approximately $1,110,000. Quotient Wealth Partners LLC bought a new position in Axon Enterprise during the first quarter valued at approximately $438,000. CX Institutional purchased a new stake in Axon Enterprise in the first quarter worth approximately $115,000. GAMMA Investing LLC grew its position in Axon Enterprise by 11.8% in the 1st quarter. GAMMA Investing LLC now owns 1,454 shares of the biotechnology company's stock worth $765,000 after purchasing an additional 154 shares during the period. Finally, DAVENPORT & Co LLC raised its stake in Axon Enterprise by 5.1% during the 1st quarter. DAVENPORT & Co LLC now owns 940 shares of the biotechnology company's stock valued at $494,000 after buying an additional 46 shares during the last quarter. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Price Performance

Shares of NASDAQ AXON traded down $27.39 during mid-day trading on Friday, hitting $843.58. 483,353 shares of the company's stock traded hands, compared to its average volume of 708,271. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.62. Axon Enterprise, Inc has a 1 year low of $346.71 and a 1 year high of $885.91. The company's 50-day moving average is $772.30 and its two-hundred day moving average is $663.05. The company has a market capitalization of $66.22 billion, a P/E ratio of 208.29, a PEG ratio of 19.36 and a beta of 1.36.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%. The firm had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. During the same quarter in the previous year, the company posted $1.20 EPS. The company's revenue for the quarter was up 32.6% compared to the same quarter last year. On average, equities analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price target on Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a report on Thursday, July 17th. Raymond James Financial reiterated an "outperform" rating and set a $855.00 price objective (up previously from $645.00) on shares of Axon Enterprise in a research report on Tuesday. UBS Group reissued a "neutral" rating and issued a $840.00 target price (up from $820.00) on shares of Axon Enterprise in a research report on Tuesday. Bank of America boosted their price target on Axon Enterprise from $895.00 to $1,000.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Wolfe Research assumed coverage on shares of Axon Enterprise in a research note on Monday, July 7th. They issued an "outperform" rating on the stock. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $837.69.

Insiders Place Their Bets

In related news, CRO Cameron Brooks sold 3,000 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $740.76, for a total value of $2,222,280.00. Following the sale, the executive directly owned 19,447 shares of the company's stock, valued at $14,405,559.72. This represents a 13.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Joshua Isner sold 905 shares of the business's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total value of $702,632.95. Following the transaction, the president owned 268,735 shares of the company's stock, valued at $208,643,166.65. This trade represents a 0.34% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,642 shares of company stock valued at $25,090,528. 4.40% of the stock is currently owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.